Mitomycin Accord

Mitomycin, the active ingredient in Mitomycin Accord, is an antineoplastic antibiotic presented as an injectable solution for intravenous and intravesical use. It treats various solid tumours such as bladder, gastric, pancreatic, non‑small cell lung and head‑and‑neck cancers in adult patients.

GNH USA supplies Mitomycin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin is an antineoplastic antibiotic used in chemotherapy regimens for several solid tumour types. - Bladder cancer: employed as intravesical therapy to reduce tumour recurrence. - Gastric cancer: incorporated into combination regimens to improve response rates. - Pancreatic cancer: used alongside other agents to enhance cytotoxic effect. - Non‑small cell lung cancer: part of multi‑drug protocols for advanced disease. - Head and neck cancer: administered in combination to increase tumour control.

Adverse reactions may occur with mitomycin therapy.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during treatment. - Myelosuppression: reduced white blood cells, platelets and red cells. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: hair loss that may be temporary.

Serious or Rare Side Effects: - Severe bone‑marrow suppression: can lead to life‑threatening infections. - Pulmonary fibrosis: progressive scarring of lung tissue. - Hemolytic‑uremic syndrome: renal failure with hemolysis and low platelets. - Anaphylactic reactions: rare but potentially fatal hypersensitivity. - Secondary malignancies: risk of new cancers after prolonged exposure.

Mitomycin therapy requires careful monitoring and specific safety measures. - Renal function: assess baseline creatinine and monitor during treatment. - Hematologic status: perform regular complete blood counts to detect myelosuppression. - Pulmonary health: evaluate for pre‑existing lung disease before initiation. - Concomitant chemotherapy: avoid overlapping myelosuppressive agents when possible. - Pregnancy and lactation: contraindicated unless benefits clearly outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mitomycin may interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Other alkylating agents: additive myelosuppression. - High‑dose radiation therapy: increased tissue toxicity. - Live vaccines: risk of uncontrolled infection.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., cisplatin): monitor renal function closely. - Hepatotoxic agents: observe liver enzymes regularly. - Anticoagulants: heightened bleeding risk, adjust monitoring.